Skip to main content

Prescription Cost Sharing

Economic and Health Impacts, and Implications for Health Policy

PharmacoEconomics volume 2, pages 219–237 (1992)Cite this article

Summary

Cost sharing for prescription Pharmaceuticals — in the form of copayments, coinsurance, or deductibles — is now common in healthcare systems throughout the world. Although there are no studies that directly or convincingly measure the effects of prescription cost sharing on health status or treatment outcomes, cost sharing does appear to reduce utilisation of Pharmaceuticals; however, more information is required concerning the relationship between cost sharing and prescription-filling behaviour. Additionally, outcomes studies are needed to define appropriate and inappropriate cost-sharing levels for particular groups of patients, based on income, disease, employment status, and other factors.

Cost sharing for Pharmaceuticals and other medical services is likely to increase in the near future. As a result, consumers will have a greater role in treatment decisions and will also become more interested in knowing the value of the medicines they are asked to purchase. They are therefore likely to demand pharmaceutical products that are more cost-effective and products that improve quality of life.

The increased implementation of cost-sharing programmes necessitates the adoption of appropriate cost-sharing policies, which incorporate the following general principles:

  1. 1.

    Consumers must be provided with the information required to make informed decisions, including the value of the medication, its importance in the treatment plan, and the consequences of not having the prescription filled.

  2. 2.

    Aggressive or abusive cost-sharing features that deny access to optimal pharmaceutical therapy must be avoided.

  3. 3.

    Inappropriate cost sharing, either fixed level or percentage of the prescription cost, may affect disease control and ultimately health or functional status.

  4. 4.

    Cost sharing restricted to Pharmaceuticals may encourage replacement of drug therapy with more expensive forms of treatment; therefore, cost sharing should apply to the full range of medical services to prevent service substitution.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  • Benson S, Marshall D. How employee benefit managers choose health plans. Medical Interface August, 10–21, 1990

    Google Scholar 

  • Budden MC, Lake RC. University catalogues and HMO co-payments: Simple lessons in economic rationing. Health Marketing Quarterly 8: 27–30, 1990

    PubMed  Article  CAS  Google Scholar 

  • Curtiss FR. Drug benefit design to manage selection bias. Drug Benefit Trends 3: 9–11, 1991

    Google Scholar 

  • Dickinson JG. Key to future: Restat’s 100% copay plan. Dickinson’s Pharmacy 3: 1, 7-8, 1991

    Google Scholar 

  • Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, et al. The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial. Journal of Chronic Disease 40(5): 429–437, 1987

    Article  CAS  Google Scholar 

  • Frost & Sullivan, Inc. Current issues and trends in pharmaceutical reimbursement, Fall 1990

  • Glaser M. PCS recommends percentage co-pays, generic programs. Drug Topics 23: 60, 1991

    Google Scholar 

  • Gold M, Joffe M, Kennedy TL, Tucker AM. Pharmacy benefits in health maintenance organizations. Health Affairs 8: 182–190, 1989

    PubMed  Article  CAS  Google Scholar 

  • Griffin TD. An economist’s view of patient co-payment for prescribed medicines in the European Community. International Pharmacy Journal 6: 15–18, 1992

    Google Scholar 

  • Group Health Association of America (GHAA). Benefits, premiums, and market structure in 1989. HMO Industry Profile 1: 13–14, 20–21, 57–63, 1989

    Google Scholar 

  • Group Health Association of America (GHAA). HMO industry profile, 1990

  • Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of Pharmaceuticals in a health maintenance organization. Medical Care 28(10): 907–917, 1990

    PubMed  Article  CAS  Google Scholar 

  • Health Insurance Association of America (HIAA). The health insurance industry strategy for containing health care costs. A report to the Board of Directors, February 1990

    Google Scholar 

  • Interpharma and Medizinisch-Pharmazeutische Studiengesellschaft (MPS). Individual responsibility and social solidarity. Bonn, 1990

  • Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Social Science and Medicine 21: 1063–1069, 1985

    PubMed  Article  CAS  Google Scholar 

  • Little AD. Implications of health care reform on the pharmaceutical industry. Report to the National Pharmaceutical Council, July 15 1991

    Google Scholar 

  • Lohr KN, Brook RH, Kamberg CJ, Goldberg GA, Leibowitz A, et al. Use of selected drugs and procedures. Medical Care 24 (Suppl): 529, 1986

    Google Scholar 

  • McDonough KP, Weaver RH, Viall GD. Enalapril to lisinopril: economic impact of a voluntary angiotensin-converting enzyme-inhibitor substitution program in a staff-model health maintenance organization. Annals of Pharmacotherapy 26: 399–404, 1992

    PubMed  CAS  Google Scholar 

  • Metropolitan Life Insurance Company (Met Life). Trade-offs and choices: Health policy options for the 1990s. Survey conducted by Louis Harris and Associates Inc., New York 1991

    Google Scholar 

  • National Association of Private Psychiatric Hospitals (NAPPH). Benefits watch survey 1991. Washington, DC, 1991

  • National Pharmaceutical Council (NPC). Employers and prescription medicine benefits. National Pharmaceutical Council, Reston, Virginia 1989

    Google Scholar 

  • National Pharmaceutical Council (NPC). Pharmaceutical benefits under state medical assistance programs. National Pharmaceutical Council, Reston, Virginia. September 1991

    Google Scholar 

  • Nelson AA, Reeder CE, Dickson WM. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Medical Care 22(8): 724–736, 1984

    PubMed  Article  Google Scholar 

  • Newhouse JP, Manning WG, Morris CN. Some interim results from a controlled trial of cost sharing in health insurance. Rand Health Insurance Experiment Series, January 1982

  • Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry 22: 396–403, 1985

    PubMed  CAS  Google Scholar 

  • REMIT Consultants. Towards common pricing for pharmaceuticals in the European market. London, March 1991

  • Scott-Levin Associates. HMO/PPO organizational survey 1990. Scott-Levin Associates, Newtown, Pennsylvania 1990

    Google Scholar 

  • Scrip World Pharmaceutical News. Pharma spending slows in Italy. Scrip no. 1693, p. 3, February 19 1992a

  • Scrip World Pharmaceutical News. Faults in Italy’s new co-payment rules. Scrip no. 1688, p. 3, January 31 1992b

  • Smith DG. The effects of co-payments and generic substitution on the use and costs of prescription drugs, presented at the American Risk Association Annual Meeting, August 17, 1992, Washington DC

  • Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid. New England Journal of Medicine 317: 550–556, 1987

    PubMed  Article  CAS  Google Scholar 

  • Soumerai SB, Ross-Degnan D. Experience of state drug benefit programs. Health Affairs 9: 36–54, 1990

    PubMed  Article  CAS  Google Scholar 

  • Soumerai SM, Ross-Degnan D, Avorn J, McLaughlin TJ, Chodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New England Journal of Medicine 325: 1072–1077, 1991

    PubMed  Article  CAS  Google Scholar 

  • Weiner JP, Lyles A, Steinwachs DM, Hall KC. Impact of managed care on prescription drug use. Health Affairs 10: 140–154, 1991

    PubMed  Article  CAS  Google Scholar 

  • Wilkes D. Germany: coming to terms with reference pricing. Scrip 16–18, February 1992

Download references

Author information

Affiliations

  1. Vice President, National Pharmaceutical Council, 1894 Preston White Drive, Reston, Virginia, 22091, USA

    Richard A. Levy

Authors
  1. Richard A. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Levy, R.A. Prescription Cost Sharing. PharmacoEconomics 2, 219–237 (1992). https://doi.org/10.2165/00019053-199202030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202030-00005